Online inquiry

IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6679MR)

This product GTTS-WQ6679MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MUC16 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6679MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8724MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ14908MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ11501MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ6360MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ1567MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ12340MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ2849MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ15730MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VIR-7831
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW